News

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...
BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...
There has been a rise in deals and investment to grow US manufacturing operations, due to impending tariffs on the sector.
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as ...
When Özlem Türeci, co-founder of BioNTech, first heard about the novel coronavirus, she knew her company would have to work on a vaccine to fight it. American Amanda Anisimova upsets No. 1 Aryna ...
Investor's Business Daily on MSN18d
BioNTech ADR Earns Relative Strength Rating Upgrade
BioNTech ADR BNTX saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73. Please watch the video at Investors.com - What Are The Magnificent Seven Stocks?
The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...
Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.
BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur ...
Pfizer, BioNTech reach $1.95 billion covid-19 vaccine deal with U.S. government. The contract is the largest yet under the Trump administration’s Operation Warp Speed program, and will start ...
Before new versions of the Omicron strain took hold in the U.S., Pfizer Inc. and BioNTech SE had begun tinkering with their widely used Covid-19 vaccine. In May, researchers tracking how ...